Efficacy of inhaled nebulised unfractionated heparin to prevent intubation or death in hospitalised patients with COVID-19: an investigator-initiated international meta-trial of randomised clinical studies
Year: 2025
Type: article
Abstract: Background: Inhaled nebulised unfractionated heparin (UFH) has a strong rationale as a treatment for severe respiratory infections, including COVID-19, due to its antiviral, anti-inflammatory, and anti-coagulant properties, which may prevent viral entry, lung injury progression, and pulmonary thrombosis. We aimed to evaluate the efficacy of inhaled nebulised UFH to prevent intubation or death in hospitalised COVID-19 patients. Methods: In this prospective, a priori set up and defined, collaborative meta-trial of six randomised clinical studies, adult hospitalised but not intubated COVID-19 patients were randomly assigned to inhaled nebulised UFH on top of standard of care or standard of care alone. The dose and method of nebulisation was specific to each study. The primary outcome was intubation or death, assessed at the longest follow-up after randomisation. The meta-trial was registered at ClinicalTrials.gov ID NCT04635241. Findings: Between June 2020 and December 2022, 478 patients from 10 hospitals in six countries (Argentina, Brazil, Egypt, Indonesia, Ireland and USA) were enrolled. The odds ratio (OR) for intubation or death was 0.43 (0.26-0.73, p = 0.001); the OR for in-hospital mortality was 0.26 (0.13-0.54, p < 0.001) with inhaled nebulised UFH compared to standard of care alone. There were no safety issues reported, including no instances of pulmonary or systemic bleeding in the nebulised UFH group. Interpretation: In patients hospitalised but not intubated for COVID-19, inhaled nebulised UFH prevented intubation and reduced mortality, without causing pulmonary or systemic bleeding. Funding: The Sponsor of the meta-trial was the INHALE-HEP Collaborative Research Group (CRG); investigators of each contributing study were members of the INHALE-HEP CRG. No funding was received for the meta-trial. The Brazilian study was funded by The J.R. Moulton Charity Trust. The Irish study was funded by a Grant from Science Foundation Ireland to Cúram, the SFI's Centre for Research in Medical Devices (Research Centre Award Reference: 13/RC/2073).
Source: EClinicalMedicine
Authors: Frank M.P. van Haren, Sarah J. Valle, Ary Serpa Neto, Marcus J. Schultz, John G. Laffey, Antonio Artigas, Barry Dixon, Alicia B. Vilaseca, Ruben A. Barbera, Tarek I. Ismail, Rabab S. Mahrous, Mohamed Badr, Gilberto DeNucci, Carlos Sverdloff, Marta Camprubi-Rimblas, David W. Cosgrave, Bairbre McNicholas, Catriona Cody, Gerard Curley, Thomas L. Smoot, Sabrina Staas, Khine Sann, Caitlin Sas, Anusha Belani, Christopher Hillman, Sidharta Kusuma Manggala, Dita Aditianingsih, Adhrie Sugiarto, Mira Yulianti, Herikurniawan Herikurniawan, Robert Sinto, Aino Nindya Auerkari, Septian Adi Permana, Ashley Woodcock, Mary Carroll, Tom Wilkinson, Dave Singh, Janis Kay Shute, Miles Carroll, Clive Page
Institutions: Australian National University, St George Hospital, Austin Hospital, Monash University, Mahidol University, Mahidol Oxford Tropical Medicine Research Unit, Amsterdam University Medical Centers, Ollscoil na Gaillimhe – University of Galway, University Hospital Galway, Universitat Autònoma de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Corporació Sanitària Parc Taulí, Institute of Research and Innovation Parc Tauli, St Vincent's Hospital Melbourne, Helwan University, Alexandria University, Universidade de São Paulo, Universidade Estadual de Campinas (UNICAMP), Connolly Hospital Blanchardstown, Royal College of Surgeons in Ireland, Beaumont Hospital, Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo, University of Indonesia, University of Manchester, Centre for Human Genetics, University of Oxford, University of Southampton, Medicines Evaluation Unit, University of Portsmouth, King's College London
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,780
OpenAlex ID: W4415854992